Continue your subscription
If you don’t take any action, this will be your default option. You'll receive an email about reviewing your subscription, and no changes are needed if you’d like to continue. You can also find the new prices listed here.
NUMAN UPDATE
MOUNJARO PRICE CHANGES
Eli Lilly has increased Mounjaro prices. We know this raises concerns, but your progress is our priority. Here's everything you need to know about what’s happening, what we’re doing, and what options you have to continue your journey of living a healthier, happier, longer life.
The bottom line
Eli Lilly, the manufacturer of Mounjaro, has raised its prices. We’ve updated ours too, but we’re not passing on the full increase. Your progress, affordability, and results come first.
We understand this price change may affect your weight loss plans. Whether you’re an existing patient or new to Numan, below are the steps to keep moving forward with the solution that works best for you.
Numan patients: your options
If you’re on other weight loss medications, there’s nothing you need to do. These are made by different manufacturers, and their prices haven't changed. For Mounjaro patients, the price of your September order will not have increased. Take your time to plan your next steps and decide how you want to move forward on your health journey. Not sure what to do? Here are your options:
Lower your dose
Consider reducing your Mounjaro dose, which could help mitigate the price increase while still helping you achieve results. Our clinicians can advise you.
Switch programmes
Request to move to a different treatment programme, which may be a more affordable alternative with similarly successful results.
New patients: your options
If you’re new to Numan and planning to join our Weight Loss Programme, here’s what you need to know:
Mounjaro
If clinically approved, you may be prescribed Mounjaro. While the manufacturer’s price rise has meant an increase for us, we haven't raised prices to the same extent. You can find the updated price list here.
Wegovy
Wegovy is a prescription weight loss medication. If clinically approved, you may start the programme, along with full access to the app. Wegovy works in a similar way to Mounjaro and is currently unaffected by price changes.
Alli
Alli is an over-the-counter weight loss treatment containing orlistat. It works by blocking around a quarter of the fat you eat from being absorbed and is taken with up to three main meals a day. Its price is unaffected by these changes.
Switching programmes with Numan
Here’s what you need to know.
Step one
Submit a request in the app. If you’re new to Numan, complete the online consultation instead.
Step two
A clinician will assess your medical background and preferences to determine if your request is right for you.
Step three
If approved, your treatment will be delivered along with clear guidance on transitioning from your current medication.
“Whether you stay on Mounjaro, adjust your dose, or switch to a different treatment, we’ll keep your plan safe, transparent, and tailored to you.”
Dr Luke Pratsides, Head of Clinical Governance
Understanding your choices
Below is a summary of the key differences between Mounjaro, Wegovy, and Alli.
| Feature | Mounjaro | Wegovy | Alli |
|---|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide | Orlistat |
| Mechanism of action | Mimics the effects of GIP and GLP-1, which are hormones that help regulate appetite and blood sugar levels | Mimics the effect of GLP-1, a hormone that helps regulate appetite | Blocks the enzymes that break down dietary fat, preventing about a quarter of it from being absorbed by the body |
| Condition treated | Obesity | Obesity and reduced cardiovascular risk¹ | Obesity |
| Administration | Once-weekly injection | Once-weekly injection | Capsule taken orally up to three times per day with meals |
| Achievable weight loss (according to research) | Up to 22.5%² | Up to 17.5%³ | Up to 5.9%⁴ |
Latest Wegovy research
Since its UK launch in 2023, ongoing research into Wegovy has led to new developments. In 2024, it received approval for use in reducing the risk of cardiovascular events in people with cardiovascular disease.5
On top of this, new trial data, published in June 2025, suggests higher doses of semaglutide, the active ingredient in Wegovy, can deliver increased weight loss results.6
The Numan Programme
Treatments help, but habits make results last. Numan’s Weight Loss Programme pairs clinically-proven medication with one-to-one health coaching. We reject outdated diet culture and patient blame, focusing on modern, effective solutions. With the programme, you’ll receive:
Ongoing clinical care whenever it’s needed
One-to-one support from a health coach to navigate challenges and celebrate wins
Evidence-based guidance to help you understand your body and protect your health
Support when you need it
If you’re still concerned about the ongoing changes, don’t hesitate to reach out to our Customer Care Team. We’re here to help, answer your questions, and guide you through any concerns every step of the way.
FAQS
Your questions answered
KNOWLEDGE
Learn more about our weight loss treatments
/ "Eva")
References
1 Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England journal of medicine. 2023;389(24): 2221–2232.
2Ard J, Lee CJ, Gudzune K, Addison B, Lingvay I, Cao D, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-Diabetes, obesity & metabolism. 2025;27(9): 5064–5071.
3 Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial: The STEP 4 randomized clinical trial. JAMA: the journal of the American Medical Association. 2021;325(14): 1414–1425.
4 Jain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab. 2011;15(2):99–104.
5 Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England journal of medicine. 2023;389(24): 2221–2232.
6 Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17.
Start your treatment journey
Answer a few simple questions to get the treatment you need.